Clinical Trial Update: Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial comparing bevacizumab alone versus bevacizumab plus TPI-287 for recurrent glioblastoma; trial terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Central Nervous System Neoplasms
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TPI-287

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Neoplasms, Central Nervous System Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-06-05